The recent positive surprise over its Japanese milestone payment highlights how unwarranted investors’ negativity towards Pledpharma is, in our view. A 60% likelihood of Phase III trial success positions PledOx to become the world’s first approved treatment for oxaliplatin-induced peripheral neuropathy and to eventually achieve near-blockbuster peak sales. Against this supportive backdrop, we see even greater value in the stock now.